No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CSL240621C420000
- 2.76
- -4.34-61.13%
15min DelayTrading Jun 12 14:17 ET
2.76High2.76Low
2.76Open7.10Pre Close1 Volume18 Open Interest420.00Strike Price276.00Turnover17.57%IV1.95%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry2.76Extrinsic Value100Contract SizeAmericanOptions Type0.3856Delta0.0325Gamma141.77Leverage Ratio-0.2664Theta0.0406Rho54.66Eff Leverage0.2556Vega
Intraday
- 5D
- 1D
News
Here's Why We Think Carlisle Companies (NYSE:CSL) Might Deserve Your Attention Today
Ameritex Homes Announces Self-Touring Technology Across Community Developments
DALLAS, June 10, 2024 /PRNewswire/ -- Ameritex Homes, a member of Winchester Carlisle Companies, announces the use of self-showing home tour technology across new communities. Homes in community deve
Shareholders Would Enjoy A Repeat Of Carlisle Companies' (NYSE:CSL) Recent Growth In Returns
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earn
$1000 Invested In This Stock 10 Years Ago Would Be Worth $4,900 Today
Carlisle Companies (NYSE:CSL) has outperformed the market over the past 10 years by 6.64% on an annualized basis producing an average annual return of 17.06%. Currently, Carlisle Companies has a marke
Express News | NYSE Order Imbalance 52360.0 Shares on Buy Side
Zacks Industry Outlook Highlights Carlisle, Griffon and ITT
Comments
The share price has tracked EPS growth, suggesting market sentiment towards the shares remains steady. The stock's recent performance has improved, with a better one-year total shareholder return than the five-year return. Dividends have enhanced the total shareholder return.
CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
The positive trends in Carlisle Companies' ROCE and its ability to consistently reinvest in itself make it an attractive investment. Investors are expecting more growth in the future. However, it's important to check if these trends will continue.
The stock is seen as overpriced by valuation models, making it less attractive for purchase. With the company's low likelihood of significant earnings growth, its investment appeal is diminished. Profits could be made if share prices meet realistic values.
Read more